Supportive care of the older cancer patient

Critical Reviews in Oncology/Hematology

Volumn 48, Issue SUPPL., 2003, Pages

  Balducci, Lodovico ^a   Carreca, Ignazio ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cancer; Cardiomyopathy; CHOP

Indexed keywords

ALKALOID; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAMPTOTHECIN; CAPECITABINE; CARBOPLATIN; CYTARABINE; EPIPODOPHYLLOTOXIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PREDNISONE; PYRIMIDINE; QUINOLONE DERIVATIVE; RAZOXANE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRIMETHOPRIM;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; DRUG EFFECT; FEBRILE NEUTROPENIA; GERIATRICS; HEALTH CARE COST; HEMOGLOBIN DETERMINATION; HUMAN; MUCOSA INFLAMMATION; MUSCLE ATROPHY; NEUROTOXICITY; NEUTROPENIA; PATIENT SELECTION; SEPSIS;

EID: 0141884289     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2003.06.001     Document Type: Conference Paper

References (56)

1. Yancik R., Ries L.A.G. Aging and cancer in America: demographic and epidemiologic perspectives. Hematol./Oncol. Clin., N. Am. 14:2000;17-24.
2. La Vecchia C., Lucchini F., Negri E. Cancer mortality in the elderly, 1960-1998: a worldwide approach. Oncol. Spectrums. 2:2001;386-394.
3. Repetto L, Balducci L. A case for geriatric oncology, Lancet 2002.
4. Extermann M., Balducci L., Lyman G.H. What threshold for adjuvant therapy in older breast cancer patients? J. Clin. Oncol. 18:2000;1709-1717.
5. Balducci L., Beghe' C. The application of geriatric principles to the management of the older cancer patient. Crit. Rev. Hematol. Oncol. 35:2000;147-155.
6. Cova D, BOllina M, Balducci L. Cancer Chemotherapy. In: Balducci L, Lyman GH, Ershler WH, Comprehensive geriatic oncology. Harwood Academic Publishers, in press.
7. Jacobson S.D., Cha S., Sargent D.J. Tolerability, dose intensity and benefit of 5FU based chemotherapy for advanced colorectal cancer (CRC) in the elderly. A North Central Cancer Treatment Group Study. Proc. Am. Soc. Clin. Oncol. 20:2001;384a. (Abstract 1534).
8. Stein B.N., Petrelli N.J., Douglass H.O.et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Cancer. 75:1995;11-17.
9. Atillasoy E., Holt P.R. Gastrointestinal proliferation and aging. J. Gerontol. 48:1993;B43-B49.
10. Christman K., Muss H.B., Case D.et al. Chemotherapy of metastatic breast cancer in the elderly. J. Am. Med. Assoc. 268:1992;57-62.
11. Ibrahim N., Frye D.K., Buzdar A.U.et al. Doxorubicin based combination chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch. Int. Med. 156:1996;882-888.
12. Begg C.B., Carbone P. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer. 52:1983;1986-1992.
13. Giovannozzi-Bannon S., Rademaker A., Lai G.et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials. An Illinois Cancer center Study. J. Clin. Oncol. 12:1994;2447-2452.
14. Ibrahim N., Frye D.K., Buzdar A.U.et al. Doxorubicin based combination chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch. Int. Med. 156:1996;882-888.
15. Gelman R.S., Taylor S.G. Cyclophosphamide Methotrexate and 5Fluorouracil chemotherapy in women more than 65 year oldwith advanced breast cancer. The elimination of age trends in toxicity by using doses based on creatinine clearance. J. Clin. Oncol. 2:1984;1406-1414.
16. Kim Y.J., Rubenstein E.B., Rolston K.V.et al. Colony-stimulating factors (CSFs) may reduce complications and death in solid tumor patients with fever and neutropenia. Proc. ASCO. 19:2000;612a. (Abstract 2411).
17. Crivellari D., Bonetti M., Castiglione-Gertsch M.et al. Burdens and benefits of adjuvant Cyclophosphamide, Methotrexate and Fluorouracil and Tamoxifen for elderly patients with breast cancer: The international Breast cancer Study Group Trial vii. J. Clin. Oncol. 18(7):2000;1412-1422.
18. Dees E.C., O'Reilly S., Goodman S.N.et al. A prospective pharmacologic evaluation of age-related toxicity chemotherapy in women with breast cancer. Cancer Invest. 18:2000;521-529.
19. Bertini M., Freilone R., Vitolo U.et al. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasiblity and efficacy of an intensive multidrug regimen. Leuk. Lymphoma. 22:1996;483-493.
20. Zinzani P.G., Storti S., Zaccaria A.et al. Elderly aggressive histology non-Hodgkin's lymphoma: first line VNCOP-B Regimen: expereince on 350 patients. Blood. 94:1999;33-38.
21. Bjorkholm M., Osby E., Hagberg H.et al. Randomized trial of R-methu granulocyte colony stimulating factors as adjunto to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma. Proc. ASH Blood. 94(Suppl.):1999;599a. (Abstract 2665).
22. Sonneveld P., de Ridder M., van der Lelie H.et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP vs. CNOP chemotherapy. J. Clin. Oncol. 13:1995;2530-2539.
23. Tirelli U., Errante D., Van Glabbeke M.et al. CHOP is the standard regimen in patients ≥70 years of age with intermediate and high grade Non-Hodgkin's lymphoma: results of a randomized study of the European organization for the research and treatment of Cancer Lymphoma Cooperative Study. J. Clin. Oncol. 16:1998;27-34.
24. Bastion Y., Blay J.-Y., Divine M.et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment and survival. A Groupe d'Etude des Lymphomes de l'Adulte Study on 453 patients older than 69 years. J. Clin. Oncol. 15:1997;2945-2953.
25. Gomez H., Mas L., Casanova L.et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J. Clin. Oncol. 16:1998;2352-2358.
26. Coiffier B. Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma. Blood Rev. 17:2003;25-35.
27. Chrischilles E., Delgado D., Stolshek B.S.et al. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in chop treated non-Hodgkin's lymphoma. Cancer Control, JHLMCC. 9:2002;203-211.
28. Schijvers D., Highley M., DuBruyn E.et al. Role of red blood cell in pharmakinetics of chemotherapeutic agents. Anticancer Drugs. 10:1999;147-153.
29. Pierelli L., Perillo A., Greggi S.et al. Erythropoietin addition to granulocyte-colony stimulating factor abrogates life-threatening neutropenia and increases peripheral blood progenitor-cell mobilization after epirubicin Paclitaxel and Cisplatin in combination chemotherapy. J. Clin. Oncol. 17:1999;1288-1296.
30. Ratain M.J., Schilsky R.L., Choi K.E.et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin. Pharmacol. Ther. 45:1989;226-233.
31. Silber J.H., Fridman M., Di Paola R.S.et al. First-cycle Blood counts and subsequent neutropenia dose reduction or delay in early stage breast cancer therapy. J. Clin. Oncol. 16:1998;2392-2400.
32. Extermann M., Chen A., Cantor A.B.et al. Predictors of toxicity from chemotherapy in older patients. Proc. Am. Soc. Clin. Oncol. 19:2000;617a.
33. Melton L.J., khosla S., Crowson C.S.et al. Epidemiology of Sarcopenia. J. Am. Ger. Soc. 48:2000;625-630.
34. Astani A., Smith R.C., Allen B.J. The predictive value of body proteins for chemotherapy induced toxicity. Cancer. 88:2000;713-796.
35. Spielberger R.T., Stiff P., Emmanouilides C. Efficacy of recombinant human keratinocyte growth factor (rHuKGF) in reducing mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenito cell transplantation after radiation-based conditioning. Results of a phase 2 trial. Proc. Am. Soc. Clin. Oncol. 20:2001;7a. (Abstract 25).
36. Peterson D.E., Petit R.G. Phase III study: AES14 in chemotherapy patients at risk of mucositis. Proc. Am. Soc. Clin. Oncol. 22:2003;725. (Abstract 2917).
37. Carreca I., Balducci L. Oral chemotherapy for the older cancer patient. Am. J. Cancer. 1:2002;101-108.
38. Zagonel V., babare R., Merola M.C.et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lympghoma treated with combination chemotherapy. Ann. Oncol. 5(Suppl. 2):1994;127-132.
39. Balducci L., Hardy C.H., Lyman G.H. Hematopoietic growth factors in the older cancer patient. Curr. Opin. Hematol. 8:2001;170-187.
40. Dixon D.O., Neilan B., Jones S.E.et al. Effect of age on therapeutic outcome of advanced diffuse histiocytic lymphoma. J. Clin. Oncol. 4:1986;295-305.
41. Pfreundschuh M., Truemper L., Kloess M.et al. 2-weekly vs. 3-weeklyCHOP with and without etoposidefor patients >60 years of age with aggressive non-Hodgkin's lymphoma (NHL): results of the completed NHL-B2 Trialof the DSHNHL. Blood. 100(11):2002;774a. (Abstract 3060).
42. Kerr K.G. The prophylaxis of bacterial infections in neutropenic patients. J. Antimicrob. Chemother. 44(5):1999;587-591.
43. Balducci L, Carreca I. Anemia and age: epidemiological and clinical considerations. J Am Ger Soc, in press.
44. Curt G.A. Fatigue in cancer. Br. Med. J. 322:2001;1560-1568.
45. Respini D, Jacobsen P, Thors C., et al. The prevalence and correlates of fatigue in older patients. Crit Rev Hematol Oncol, 2003;47:273-9.
46. Chaves P.H., Volpato S., Fried L. Challenging the world health organization criteria for anemia in the older woman. J. Am. Ger. Soc. 49(S3):2001;A10.
47. Kikuchi M., Inagaki T., Shinagawa N. Five-year survival of older people with anemia: variation with hemoglobin concentration. J. Am. Ger. Soc. 49:2001;1226-1228.
48. Izaks G.J., Westendorp R.G.J., Knook D.L. The definition of anemia in older persons. J. Am. Med. Assoc. 281(18):1999;1714-1717.
49. Anía B.J., Suman V.J., Fairbanks V.F.et al. Incidence of anemia in older people: an epidemiologic study in a well defined population. J. Am. Geriatr. Soc. 45:1997;825-831.
50. Pickett J.L., Theberge D.C., Brown W.S., Schweitzer S.U., Nissenson A.R. Normalizing hematocrit in dialysis patients improves brain function. Am. J. Kidney Dis. 33(6):1999;1122-1130.
51. Metivier F., Marchais S.J., Guerin A.P., Pannier B., London G.M. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol. Dial. Transplant. 15(3):2000;14-18.
52. WU W.C., Rathore S.S., Wang Y.et al. Blood transfusions in elderly patients with Acute Myocardial Infarction. N. Engl. J. Med. 345:2001;1230-1236.
53. Willis F., Pettengell R. Pegfilgrastim. Exp. Opin. Biol. Ther. 2:2002;985-992.
54. Smith R. Application of darbepoietin α a novel erythropoiesis stimulating protein in oncology. Curr. Opin. Hematol. 9:2002;228-233.
55. Lyman G.H., Kuderer N., Greene J., Balducci L. The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur. J. Cancer. 34(12):1998;1857-1864.
56. Anonymous, Integrating Economic analysis into cancer clinical trials: the national Cancer Institute-American Society of Clinical Oncology workbook. J Natl Cancer Inst Monographs 1998;24:1-28.